ALKOVE-1: FDA grants accelerated approval to neladalkib in previously treated ALK-positive NSCLC
FDA,
FDAAccelerated approval
Neladalkib (Nelkarmi)
Adults with locally advanced or metastatic ALK-positive NSCLC whose treatment for advanced disease has included alectinib as the only ALK inhibitor, or two or more ALK inhibitors and platinum-based chemotherapy
The evidence
49 %
Response rate after alectinib (67 patients)
95% CI 37–62; 52% of responses lasted 12 months or more
32 %
Response rate after two or more ALK inhibitors and chemotherapy (155 patients)
95% CI 24–40; 51% of responses lasted 12 months or more
Dose 150 mg by mouth once daily, with or without food, at the same time each day
What did the FDA approve?
Neladalkib (Nelkarmi, Nuvalent) is an ALK kinase inhibitor taken by mouth once a day. The approval is for adults with locally advanced or metastatic ALK-positive NSCLC whose treatment for advanced disease has included either alectinib as their only ALK inhibitor, or at least two ALK inhibitors together with platinum-based chemotherapy.
The application had priority review, and neladalkib had breakthrough therapy and orphan drug designations.
Why is it an accelerated approval?
The FDA’s accelerated approval program allows a medicine for a serious condition to be approved on a surrogate endpoint: a measure expected to predict clinical benefit without measuring it directly. For neladalkib, the FDA relied on how many tumors shrank and how long those responses lasted, in cohorts with no comparison group. Under the program, the company must run studies to confirm the expected benefit; if they do not, the FDA has procedures that could lead to the drug’s withdrawal.
How was ALKOVE-1 designed?
ALKOVE-1 (NCT05384626) is a phase 1/2, multicenter, open-label trial with several cohorts, sponsored by Nuvalent and still recruiting. The approval drew on two single-arm cohorts:
- 67 patients whose only ALK inhibitor for metastatic disease had been alectinib
- 155 patients who had received two or more ALK inhibitors and platinum-based chemotherapy
Responses had to be confirmed, and were judged by blinded independent central review using RECIST 1.1.
| Measure | After alectinib only | After two or more ALK inhibitors and chemotherapy |
|---|---|---|
| Patients | 67 | 155 |
| Confirmed response rate | 49% (95% CI 37–62) | 32% (95% CI 24–40) |
| Responses lasting 6 months or more | 76% | 69% |
| Responses lasting 12 months or more | 52% | 51% |
What did the trial show?
In the 67 patients previously treated with alectinib alone, 49% had a confirmed response (95% CI, 37 to 62). Of those who responded, 76% were still responding at 6 months and 52% at 12 months.
In the 155 patients previously treated with at least two ALK inhibitors and chemotherapy, 32% responded (95% CI, 24 to 40); 69% of those responses lasted at least 6 months and 51% at least 12 months.
Because the cohorts had no comparison group, these results do not measure an effect on progression-free or overall survival.
What about safety?
According to the FDA, the most common adverse reactions, in 20% of patients or more, were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema and fatigue. The label warns of hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation and embryo-fetal toxicity.
What else is approved after alectinib?
Lorlatinib received accelerated approval on November 2, 2018, for ALK-positive metastatic NSCLC that had progressed on alectinib or ceritinib as the first ALK inhibitor, or on crizotinib and at least one other ALK inhibitor. The FDA lists that approval’s benefit as verified on March 3, 2021.
Sources
- FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer. US Food and Drug Administration. November 17, 2026.
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1). ClinicalTrials.gov, NCT05384626.
- Accelerated Approval Program. US Food and Drug Administration.
- FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC. US Food and Drug Administration. November 2, 2018.
- Verified Clinical Benefit: Cancer Accelerated Approvals. US Food and Drug Administration.
Take-home
The FDA granted accelerated approval to neladalkib for adults with locally advanced or metastatic ALK-positive NSCLC previously treated with alectinib, or with two or more ALK inhibitors and platinum-based chemotherapy. It rests on response rates of 49% and 32% in two cohorts of the single-arm ALKOVE-1 trial.





